PL358579A1 - Analogi tamandaryny i didemniny oraz sposoby ich wytwarzania i stosowania - Google Patents

Analogi tamandaryny i didemniny oraz sposoby ich wytwarzania i stosowania

Info

Publication number
PL358579A1
PL358579A1 PL01358579A PL35857901A PL358579A1 PL 358579 A1 PL358579 A1 PL 358579A1 PL 01358579 A PL01358579 A PL 01358579A PL 35857901 A PL35857901 A PL 35857901A PL 358579 A1 PL358579 A1 PL 358579A1
Authority
PL
Poland
Prior art keywords
methods
tamandarin
making
analogs
didemnin analogs
Prior art date
Application number
PL01358579A
Other languages
English (en)
Inventor
Madeleine M. Joullie
Bo Liang
Xiaobin Ding
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/545,848 external-priority patent/US6509315B1/en
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of PL358579A1 publication Critical patent/PL358579A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL01358579A 2000-04-07 2001-04-09 Analogi tamandaryny i didemniny oraz sposoby ich wytwarzania i stosowania PL358579A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/545,848 US6509315B1 (en) 2000-04-07 2000-04-07 Didemnin analogs and fragments and methods of making and using them
US09/767,080 US7064105B2 (en) 2000-04-07 2001-01-22 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them

Publications (1)

Publication Number Publication Date
PL358579A1 true PL358579A1 (pl) 2004-08-09

Family

ID=27068046

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01358579A PL358579A1 (pl) 2000-04-07 2001-04-09 Analogi tamandaryny i didemniny oraz sposoby ich wytwarzania i stosowania

Country Status (17)

Country Link
US (1) US7651997B2 (pl)
EP (1) EP1276491B9 (pl)
JP (1) JP2003535048A (pl)
AT (1) ATE339963T1 (pl)
AU (1) AU2001251498A1 (pl)
BR (1) BR0109958A (pl)
CA (1) CA2405779A1 (pl)
CY (1) CY1105866T1 (pl)
DE (1) DE60123232T2 (pl)
DK (1) DK1276491T3 (pl)
ES (1) ES2272462T3 (pl)
IL (1) IL152111A0 (pl)
MX (1) MXPA02009943A (pl)
NZ (1) NZ521844A (pl)
PL (1) PL358579A1 (pl)
RU (1) RU2323000C2 (pl)
WO (1) WO2001076616A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU780417B2 (en) * 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
HK1054191A1 (zh) 2000-10-12 2003-11-21 Pharma Mar, S.A. 施用aplidine時同時使用myoprotector的癌症治療
CN1761480B (zh) 2003-03-12 2012-09-26 达纳-法伯癌症协会有限公司 用于多发性骨髓瘤的治疗的aplidine
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
CN1819837A (zh) * 2003-03-21 2006-08-16 玛德琳·M.·茹利 Tamandarin类似物及其片段以及制备和使用方法
US8258098B2 (en) 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
US20100240595A1 (en) * 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
MX2010009697A (es) * 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
WO2010009334A1 (en) 2008-07-17 2010-01-21 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
WO2013041969A2 (en) * 2011-09-21 2013-03-28 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
US10676504B2 (en) 2015-03-06 2020-06-09 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
AU2016230008B2 (en) 2015-03-06 2020-08-27 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
JP2019064920A (ja) * 2016-02-16 2019-04-25 国立大学法人東北大学 環状デプシペプチド化合物
SI4101855T1 (sl) 2017-04-27 2024-03-29 Pharma Mar S.A. Protitumorske spojine
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
PE20231069A1 (es) 2020-03-02 2023-07-17 Pharma Mar Sa Compuestos para su uso en el tratamiento de la infeccion por coronavirus
CA3169544A1 (en) 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions
WO2022140144A1 (en) 2020-12-21 2022-06-30 Colorado State University Research Foundation Synthesis of structural analogs of largazole and associated compounds
CN115976141B (zh) * 2021-10-14 2025-10-31 浙江珲达生物科技有限公司 一种发酵制备Didemnin B的培养基及其制备方法
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US5137870A (en) * 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4782135A (en) * 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE4120327A1 (de) * 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
EP0836851A1 (en) * 1996-10-21 1998-04-22 Virbac S.A. Amidine compounds for use in treating ecto or endo parasitic diseases and systemic parasite control compositions
EP0973518B1 (en) 1996-10-24 2006-03-29 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
PT956033E (pt) * 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1819837A (zh) * 2003-03-21 2006-08-16 玛德琳·M.·茹利 Tamandarin类似物及其片段以及制备和使用方法

Also Published As

Publication number Publication date
RU2323000C2 (ru) 2008-04-27
EP1276491B1 (en) 2006-09-20
JP2003535048A (ja) 2003-11-25
MXPA02009943A (es) 2003-04-25
WO2001076616A1 (en) 2001-10-18
AU2001251498A1 (en) 2001-10-23
ES2272462T3 (es) 2007-05-01
US20070129289A1 (en) 2007-06-07
RU2002129885A (ru) 2004-03-27
BR0109958A (pt) 2003-05-27
CA2405779A1 (en) 2001-10-18
DE60123232T2 (de) 2007-11-08
CY1105866T1 (el) 2011-02-02
NZ521844A (en) 2004-07-30
US7651997B2 (en) 2010-01-26
DK1276491T3 (da) 2007-02-05
EP1276491A4 (en) 2004-08-25
EP1276491A1 (en) 2003-01-22
IL152111A0 (en) 2003-07-31
ATE339963T1 (de) 2006-10-15
EP1276491B9 (en) 2007-02-28
DE60123232D1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
IL152111A0 (en) Tamandarin and didemnin analogs and methods of making and using them
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
EA200401591A1 (ru) Керамические аноды и способ их изготовления
HRP20030288B1 (en) Growth hormone secretagogues
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
NZ523367A (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
AU5354301A (en) Nucleic acid sequences to proteins involved in tocopherol synthesis
EP1306427A4 (en) METHOD FOR THE REPRODUCTION OF NATURAL KILLER CELLS
NO20031033L (no) Reseptor i EDb-fibronectindomene
EP1480998A4 (en) INTERMEDIATES AND METHODS FOR MAKING OXYTOCIN ANALOGUES HEPTAPEPTIDE
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
AU2003220441A8 (en) Dipeptidic growth hormone secretagogues
UA80871C2 (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
PL375350A1 (pl) Pochodne indolu i ich zastosowanie jako ligandów 5-HT
DE60116664D1 (de) Indolocarbazol-antikrebsmittel und verfahren zu ihrer verwendung
TW200505413A (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
AR033415A1 (es) Composiciones
ATE453623T1 (de) Synthese von dipeptidanaloga
UA49752A (uk) Спосіб визначення концентрації пентапептидного аналога вазопресину у водному розчині

Legal Events

Date Code Title Description
VOID Decisions declaring the decisions on the grant of the patent lapsed
DISD Decisions on discontinuance of the proceedings of a derived patent or utility model

Ref document number: 387496

Country of ref document: PL